Rapid progress in understanding and treating lymphoid malignancies is occurring at many levels, including molecular and cellular biology, immunology and clinical trials. Rapid, peer-reviewed publication in the on-line journal Lymphoma and Chronic Lymphocytic Leukemias will reach basic and clinical investigators with broad translational impact. In addition, manuscripts will be widely available world-wide.Areas of interest include lymphoid biology as it relates to development of lymphoma and lymphoid leukemia, pre-clinical investigations, as well as clinical therapeutic interventions. Publications in this journal will foster communications among basic scientists, translational investigators and clinicians to enhance our understanding and treatment of lymphoma and CLL.
What is the advantage to you of publishing in Lymphoma and Chronic Lymphocytic Leukemias?
- Full open access: everyone can read your article and you retain copyright in it
- Publishing decision within 2 weeks of submission
- Your paper will not be rejected due to lack of space and will be published immediately on acceptance
- Prompt and fair peer review from two expert peer reviewers
- Frequent updates on your paper’s status
- Friendly responsive staff
Lymphoma and Chronic Lymphocytic Leukemias is a journal that publishes papers in basic and clinical research into lymphoma and chronic lymphoid leukemia..
What a previous author said:
"The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I've never had such complete communication with a journal."In summary:
The advantages of a younger journal such as Lymphoma and Chronic Lymphocytic Leukemias are numerous but in essence allow us a greater flexibility and responsiveness to authors and readers that older journals cannot match.
Next steps:
- Visit the journal's home page (full open access to all articles)
- Get a manuscript in preparation approved for peer review
- Submit a manuscript now (fast 3-step submission process)
- Send me an inquiry
Yours sincerely,
Dr Mitchell Smith
Editor-in-Chief
Lymphoma and Chronic Lymphocytic Leukemias
Posts
